Compare · MTRI vs VNDA
MTRI vs VNDA
Side-by-side comparison of Mentari Therapeutics Inc. (MTRI) and Vanda Pharmaceuticals Inc. (VNDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTRI and VNDA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MTRI is the larger of the two at $924.2M, about 4.0x VNDA ($230.4M).
- MTRI has been more active in the news (20 items in the past 4 weeks vs 9 for VNDA).
- VNDA has more recent analyst coverage (6 ratings vs 0 for MTRI).
- Company
- Mentari Therapeutics Inc.
- Vanda Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $924.2M
- $230.4M
- 1M return
- -
- -6.50%
- 1Y return
- -
- -28.62%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- News (4w)
- 20
- 9
- Recent ratings
- 0
- 6
Mentari Therapeutics Inc.
The Company is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The Company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Latest MTRI
- Amendment: SEC Form SCHEDULE 13G/A filed by Mentari Therapeutics Inc.
- Mentari Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form SCHEDULE 13G filed by Mentari Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Mentari Therapeutics Inc.
- SEC Form SCHEDULE 13D filed by Mentari Therapeutics Inc.
- Officer Seurer Jerad G. was granted 257,000 stock options (SEC Form 4)
- Director Pernice Michelle Patricia was granted 37,000 stock options (SEC Form 4)
- Officer Divis Gregory J was granted 1,560,599 stock options (SEC Form 4)
- Director Bruno Julianne was granted 37,000 stock options (SEC Form 4)
- Officer Hagen Brett R was granted 171,000 stock options (SEC Form 4)
Latest VNDA
- Amendment: SEC Form SCHEDULE 13G/A filed by Vanda Pharmaceuticals Inc.
- NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week
- SEC Form SCHEDULE 13G filed by Vanda Pharmaceuticals Inc.
- Director Duncan Charles Cliff bought $38,094 worth of shares (10,000 units at $3.81), increasing direct ownership by 10% to 108,701 units (SEC Form 4)
- Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
- SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.
- SEC Form 8-K filed by Vanda Pharmaceuticals Inc.
- Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
- Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
- Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026